.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

SANCTURA XR Drug Profile

« Back to Dashboard
Sanctura Xr is a drug marketed by Allergan and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has thirteen patent family members in nine countries.

The generic ingredient in SANCTURA XR is trospium chloride. There are sixteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the trospium chloride profile page.

Summary for Tradename: SANCTURA XR

Patents:5
Applicants:1
NDAs:1
Drug Prices: :see details
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
SANCTURA XR
trospium chloride
CAPSULE, EXTENDED RELEASE;ORAL022103-001Aug 3, 2007DISCNNo7,759,359► subscribe ► subscribe
Allergan
SANCTURA XR
trospium chloride
CAPSULE, EXTENDED RELEASE;ORAL022103-001Aug 3, 2007DISCNNo7,781,449► subscribe ► subscribe
Allergan
SANCTURA XR
trospium chloride
CAPSULE, EXTENDED RELEASE;ORAL022103-001Aug 3, 2007DISCNNo7,763,635► subscribe ► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: SANCTURA XR

Drugname Dosage Strength RLD Submissiondate
trospium chlorideExtended-release Capsules60 mgSanctura XR3/2/2009

Premature patent expiration for: SANCTURA XR

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
7,410,978
SANCTURA XR
August 12, 2016

International Patent Family for Tradename: SANCTURA XR

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2005046684► subscribe
Austria493981► subscribe
European Patent Office2210605► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc